138 related articles for article (PubMed ID: 34454058)
21. Successful targeting of the
Wu X; Zhang D; Shi M; Wang F; Li Y; Lin Q
Ann Transl Med; 2021 Oct; 9(19):1507. PubMed ID: 34805369
[TBL] [Abstract][Full Text] [Related]
22. Patients with neuregulin 1 (NRG1) rearranged cancer are suitable for the theranostic approach and targeted therapy.
Ondič O; Ptáková N; Janovský V; Vančurová J; Hósová M; Michal M; Pešek M
Klin Onkol; 2022; 35(4):271-275. PubMed ID: 35989083
[TBL] [Abstract][Full Text] [Related]
23. Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugs.
Liu SV
Future Oncol; 2022 Aug; 18(26):2865-2870. PubMed ID: 35876504
[TBL] [Abstract][Full Text] [Related]
24. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.
Fernandez-Cuesta L; Thomas RK
Clin Cancer Res; 2015 May; 21(9):1989-94. PubMed ID: 25501131
[TBL] [Abstract][Full Text] [Related]
25. NRG1 fusions: Biology to therapy.
Liu SV
Lung Cancer; 2021 Aug; 158():25-28. PubMed ID: 34098222
[TBL] [Abstract][Full Text] [Related]
26. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
[TBL] [Abstract][Full Text] [Related]
27. EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion.
Kim HS; Han JY; Shin DH; Lim KY; Lee GK; Kim JY; Jacob W; Ceppi M; Weisser M; James I
Lung Cancer; 2018 Oct; 124():71-75. PubMed ID: 30268483
[TBL] [Abstract][Full Text] [Related]
28. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
Werr L; Plenker D; Dammert MA; Lorenz C; Brägelmann J; Tumbrink HL; Klein S; Schmitt A; Büttner R; Persigehl T; Shokat KM; Wunderlich FT; Schram AM; Peifer M; Sos ML; Reinhardt HC; Thomas RK
Mol Cancer Ther; 2022 May; 21(5):821-830. PubMed ID: 35247925
[TBL] [Abstract][Full Text] [Related]
29. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Kohno T; Nakaoku T; Tsuta K; Tsuchihara K; Matsumoto S; Yoh K; Goto K
Transl Lung Cancer Res; 2015 Apr; 4(2):156-64. PubMed ID: 25870798
[TBL] [Abstract][Full Text] [Related]
30. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
31. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Shin DH; Jo JY; Han JY
Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
[TBL] [Abstract][Full Text] [Related]
32. CD74-NRG1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological Characteristics of NRG1 Fusion-Positive Solid Tumors in Korean Patients.
Cha YJ; Lee C; Joo B; Kim KA; Lee CK; Shim HS
Cancer Res Treat; 2023 Oct; 55(4):1087-1095. PubMed ID: 37321274
[TBL] [Abstract][Full Text] [Related]
34. Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer.
Ogier C; Colombo PE; Bousquet C; Canterel-Thouennon L; Sicard P; Garambois V; Thomas G; Gaborit N; Jarlier M; Pirot N; Pugnière M; Vie N; Gongora C; Martineau P; Robert B; Pèlegrin A; Chardès T; Larbouret C
Cancer Lett; 2018 Sep; 432():227-236. PubMed ID: 29935372
[TBL] [Abstract][Full Text] [Related]
35. Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements.
Zhang X; Li L; Gao F; Liu B; Li J; Ren S; Peng S; Qiu W; Pu X; Ye Q
Diagn Pathol; 2024 Jan; 19(1):1. PubMed ID: 38173003
[TBL] [Abstract][Full Text] [Related]
36. Accurate and efficient detection of gene fusions from RNA sequencing data.
Uhrig S; Ellermann J; Walther T; Burkhardt P; Fröhlich M; Hutter B; Toprak UH; Neumann O; Stenzinger A; Scholl C; Fröhling S; Brors B
Genome Res; 2021 Mar; 31(3):448-460. PubMed ID: 33441414
[TBL] [Abstract][Full Text] [Related]
37. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
38. VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.
Jung Y; Yong S; Kim P; Lee HY; Jung Y; Keum J; Lee S; Kim J; Kim J
J Thorac Oncol; 2015 Jul; 10(7):1107-11. PubMed ID: 26134228
[TBL] [Abstract][Full Text] [Related]
39. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Adélaïde J; Huang HE; Murati A; Alsop AE; Orsetti B; Mozziconacci MJ; Popovici C; Ginestier C; Letessier A; Basset C; Courtay-Cahen C; Jacquemier J; Theillet C; Birnbaum D; Edwards PA; Chaffanet M
Genes Chromosomes Cancer; 2003 Aug; 37(4):333-45. PubMed ID: 12800145
[TBL] [Abstract][Full Text] [Related]
40. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
Reissig TM; Tzianopoulos I; Liffers ST; Rosery VK; Guyot M; Ting S; Wiesweg M; Kasper S; Meister P; Herold T; Schmidt HH; Schumacher B; Albers D; Markus P; Treckmann J; Schuler M; Schildhaus HU; Siveke JT
ESMO Open; 2023 Jun; 8(3):101539. PubMed ID: 37148593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
